Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vivo visualization of prostate-specific membrane antigen in glioblastoma.

Literature DB >> 25293865

In vivo visualization of prostate-specific membrane antigen in glioblastoma.

Johannes Schwenck¹, Ghazaleh Tabatabai, Marco Skardelly, Gerhald Reischl, Rudi Beschorner, Bernd Pichler, Christian la Fougère.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2014 PMID： 25293865 DOI： 10.1007/s00259-014-2921-5

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

5 in total

1. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.

Authors: A Gabriella Wernicke; Mark A Edgar; Ehud Lavi; He Liu; Pamela Salerno; Neil H Bander; Philip H Gutin
Journal: Arch Pathol Lab Med Date: 2011-11 Impact factor: 5.534

Review 2. Tumour vascular targeting.

Authors: Dario Neri; Roy Bicknell
Journal: Nat Rev Cancer Date: 2005-06 Impact factor: 60.716

3. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Authors: Scott T Tagawa; Matthew I Milowsky; Michael Morris; Shankar Vallabhajosula; Paul Christos; Naveed H Akhtar; Joseph Osborne; Stanley J Goldsmith; Steve Larson; Neeta Pandit Taskar; Howard I Scher; Neil H Bander; David M Nanus
Journal: Clin Cancer Res Date: 2013-05-28 Impact factor: 12.531

4. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Authors: Ali Afshar-Oromieh; Christian M Zechmann; Anna Malcher; Matthias Eder; Michael Eisenhut; Heinz G Linhart; Tim Holland-Letz; Boris A Hadaschik; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn
Journal: Eur J Nucl Med Mol Imaging Date: 2013-09-27 Impact factor: 9.236

5. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.

Authors: Natsuko Nomura; Sandra Pastorino; Pengfei Jiang; Gage Lambert; John R Crawford; Marco Gymnopoulos; David Piccioni; Tiffany Juarez; Sandeep C Pingle; Milan Makale; Santosh Kesari
Journal: Cancer Cell Int Date: 2014-03-20 Impact factor: 5.722

5 in total

28 in total

1. ⁶⁸Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.

Authors: Rita Chahinian; Ahmad El-Amine; Sayed Matar; Mostafa Annan; Ali Shamseddine; Mohamad Haidar
Journal: Asia Ocean J Nucl Med Biol Date: 2020

Review 2. Current use of PSMA-PET in prostate cancer management.

Authors: Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal: Nat Rev Urol Date: 2016-02-23 Impact factor: 14.432

3. Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas.

Authors: Roberto Andres Salas Fragomeni; Joshua R Menke; Matthias Holdhoff; Clare Ferrigno; John Joseph Laterra; Lilja B Solnes; Mehrbod S Javadi; Zsolt Szabo; Martin G Pomper; Steven P Rowe
Journal: Clin Nucl Med Date: 2017-10 Impact factor: 7.794

Review 4. ⁶⁸Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?

Authors: Christian Uprimny
Journal: Wien Med Wochenschr Date: 2017-06-02

5. The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?

Authors: Marcus Unterrainer; Maximilian Niyazi; Viktoria Ruf; Peter Bartenstein; Nathalie L Albert
Journal: Neuro Oncol Date: 2017-11-29 Impact factor: 12.300

Review 6. Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors: James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal: Neurochem Res Date: 2019-11-20 Impact factor: 3.996

7. Comparison of ⁶⁸Ga-labelled PSMA-11 and ¹¹C-choline in the detection of prostate cancer metastases by PET/CT.

Authors: Johannes Schwenck; Hansjoerg Rempp; Gerald Reischl; Stephan Kruck; Arnulf Stenzl; Konstantin Nikolaou; Christina Pfannenberg; Christian la Fougère
Journal: Eur J Nucl Med Mol Imaging Date: 2016-08-24 Impact factor: 9.236

Review 8. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors: James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal: Br J Pharmacol Date: 2016-09-23 Impact factor: 8.739

Review 9. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors: Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-15 Impact factor: 9.236

Review 10. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors: Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal: Eur J Nucl Med Mol Imaging Date: 2017-08-01 Impact factor: 9.236